Sponsor or institution

Clinical trials and research at Bristol-Myers Squibb

• 102Clinical trials
• 53Countries

Newest trials

All recruiting trials (102)

• Navlimetostat: how foods and other drugs affect its levels in healthy adult women

  This study tests how what you eat and certain medicines change the amount of Navlimetostat in healthy adult women.

  Recruiting Phase 1 Bristol-Myers Squibb · Québec, Quebec · NCT07800897

• Effect of a single dose of BMS-986446 in healthy adults and after multiple doses in people with early Alzheimer's

  This study tests how BMS-986446 behaves in the body after a single dose in healthy adults and after multiple doses in people with early Alzheimer's disease to see safety and immune response.

  Recruiting Phase 1 Bristol-Myers Squibb · Anaheim, California and 5 other locations · NCT07780383

• How Navlimetostat is processed in healthy women

  This study tests how Navlimetostat is broken down and cleared in healthy women to understand its metabolism and levels in the body.

  Recruiting Phase 1 Bristol-Myers Squibb · Madison, Wisconsin and 1 other locations · NCT07777133

• Golcadomide pharmacokinetics and safety in severe kidney impairment and ESRD

  This study tests how golcadomide behaves in the body and whether it is safe in adults with severe kidney problems or end-stage kidney disease, compared with people with normal kidney function.

  Recruiting at 3 sites Phase 1 Bristol-Myers Squibb · Chandler, Arizona and 2 other locations · NCT07763418

• Repotrectinib safety in children with NTRK fusion cancers in Japan

  This study tests the safety of repotrectinib in children and teens with NTRK fusion–positive solid tumors in Japan during routine care.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07755826

• First-line luspatercept use in adults with lower-risk transfusion-dependent MDS

  This study follows adults with lower-risk MDS who start luspatercept as part of usual care to see how often they need fewer transfusions and how their blood counts and quality of life change over up to two years.

  Recruiting Bristol-Myers Squibb · Mainz · NCT07752121

• PML risk in people with MS treated with ozanimod

  This study looks at whether people with MS who take ozanimod develop PML and how often it happens.

  Recruiting Bristol-Myers Squibb · Lawrenceville, New Jersey · NCT07732907

• Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options

  This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.

  Recruiting at 10 sites Phase 3 Bristol-Myers Squibb · Beverly Hills, California and 204 other locations · NCT07680790

• Imzokitug with Pumitamig and PDCT as first-line treatment for locally advanced or metastatic NSCLC

  This trial tests whether adding Imzokitug to Pumitamig plus platinum-doublet chemotherapy helps people with newly diagnosed locally advanced or metastatic NSCLC.

  Recruiting at 33 sites Phase 2 Bristol-Myers Squibb · Washington D.C., District of Columbia and 73 other locations · NCT07680764

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• M4 receptor occupancy with BMS-986521 in healthy adults

  This study tests how well BMS-986521 occupies M4 muscarinic receptors in healthy adults using PET imaging.

  Recruiting Phase 1 Bristol-Myers Squibb · Leuven · NCT07655518

• BMS-986533 safety and PK in healthy adults with food, pH, and drug interactions

  This study tests how safe BMS-986533 is and how it behaves in the body in healthy adults, and looks at how food, stomach pH, and other medicines might affect its absorption.

  Recruiting Phase 1 Bristol-Myers Squibb · Lincoln, Nebraska · NCT07629999

• Mavacamten outcomes and real-world patient and physician experiences for obstructive HCM in the US

  See how mavacamten works and what patients and doctors experience for adults with obstructive hypertrophic cardiomyopathy treated in US community practice.

  Recruiting Bristol-Myers Squibb · Bollington, Macclesfield · NCT07557498

• Navlimetostat: a first-in-human look at two tablet formats in healthy adults

  This early-phase study tests whether two tablet formulations of Navlimetostat behave similarly in healthy adult women who aren’t of childbearing potential.

  Recruiting Phase 1 Bristol-Myers Squibb · Decatur, Georgia and 3 other locations · NCT07544628

• Mavacamten use and effectiveness in adults with obstructive hypertrophic cardiomyopathy in Japan

  This project will see how well mavacamten works and how safe it is for adults in Japan with symptomatic obstructive hypertrophic cardiomyopathy who are receiving cibenzoline.

  Recruiting Bristol-Myers Squibb · Minato-ku, Tokyo · NCT07541833

• Navlimetostat for MTAP-deleted solid tumors: monotherapy and combination therapy

  This study tests Navlimetostat alone and with other cancer drugs in people with advanced solid tumors that lack MTAP, to see if it is safe and if it can help shrink tumors.

  Recruiting at 35 sites Phase 2 Bristol-Myers Squibb · San Francisco, California and 57 other locations · NCT07492680

• BMS-986528 in people with hard-to-treat rheumatoid arthritis

  This study tests BMS-986528 to see if it is safe and tolerable and to gather early data on how it behaves in the body and whether it might slow rheumatoid arthritis.

  Recruiting at 10 sites Phase 1/2 Bristol-Myers Squibb · La Jolla, California and 38 other locations · NCT07412704

• Mavacamten treatment for obstructive hypertrophic cardiomyopathy in Japan

  This project will try mavacamten in patients in Japan with obstructive hypertrophic cardiomyopathy to see if it works well and is safe during routine care.

  Recruiting Bristol-Myers Squibb · Tokyo · NCT07383025

• Xanomeline and trospium chloride (KarXT) treatment for adults with schizophrenia

  This project will follow adults with schizophrenia in the U.S. who start KarXT to see how well it works and what side effects occur.

  Recruiting at 24 sites Bristol-Myers Squibb · Bryant, Arkansas and 67 other locations · NCT07379827

• Pumitamig vs pembrolizumab for first-line advanced NSCLC with PD‑L1 ≥50% (ROSETTA Lung-202)

  This will test if pumitamig works better than pembrolizumab as the first treatment for people with advanced non-small cell lung cancer and PD‑L1 levels of 50% or higher.

  Recruiting at 180 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 282 other locations · NCT07361510

• Pumitamig versus durvalumab after chemoradiation for unresectable stage III NSCLC

  This trial tests whether Pumitamig or durvalumab works better to keep unresectable stage III non-small cell lung cancer from coming back after concurrent chemoradiation.

  Recruiting at 201 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 258 other locations · NCT07361497

• Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in Chinese adults

  This project will test how well mavacamten works for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy when used in everyday clinical care.

  Recruiting at 10 sites Bristol-Myers Squibb · Beijing, Beijing Municipality and 14 other locations · NCT07361289

• Asia MDS Registry: Real-world Insights from Asia

  This registry collects real-world data on adults with myelodysplastic syndromes in Asia to see how they are diagnosed, treated, and what outcomes they experience.

  Recruiting Bristol-Myers Squibb · Singapore and 2 other locations · NCT07355478

• BMS-986525 alone and with nivolumab for relapsed or refractory small cell lung cancer

  This trial will test whether BMS-986525, alone or together with nivolumab, is safe and tolerable for people whose small cell lung cancer has returned or not responded to prior platinum chemotherapy.

  Recruiting at 10 sites Phase 1/2 Bristol-Myers Squibb · Detroit, Michigan and 12 other locations · NCT07325136

• Pumitamig alone or with ipilimumab or cabozantinib for advanced kidney cancer

  This trial will test whether pumitamig by itself or combined with ipilimumab or cabozantinib helps people with advanced renal cell carcinoma.

  Recruiting at 34 sites Phase 1/2 Bristol-Myers Squibb · Palo Alto, California and 94 other locations · NCT07293351

• Pumitamig alone or with ipilimumab for first-line advanced or unresectable liver cancer

  This trial will test whether pumitamig, alone or combined with ipilimumab, is safe and tolerable for people with advanced or unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 38 sites Phase 1/2 Bristol-Myers Squibb · Duarte, California and 66 other locations · NCT07291076

• KarXT for treating schizophrenia in teens (EMERGENT TEEN)

  This trial will test whether KarXT can help reduce schizophrenia symptoms in adolescents.

  Recruiting at 18 sites Phase 3 Bristol-Myers Squibb · Anaheim, California and 36 other locations · NCT07288567

• KarXT + KarX-EC for irritability in kids and teens with autism

  This study tests whether KarXT plus KarX-EC can reduce irritability in children and adolescents with autism.

  Recruiting at 3 sites Phase 3 Bristol-Myers Squibb · Phoenix, Arizona and 66 other locations · NCT07285798

• KarXT plus KarX-EC for irritability in children and teens with autism

  This study tests whether KarXT with KarX-EC, compared to a matching placebo, can reduce irritability in kids and adolescents who have autism.

  Recruiting at 4 sites Phase 3 Bristol-Myers Squibb · Dothan, Alabama and 40 other locations · NCT07284745

• Safety and drug levels of BMS-986521 in healthy adults

  This trial will test how safe and tolerable BMS-986521 is in healthy adults, measure drug levels after single and multiple doses, and see if food affects those levels.

  Recruiting Phase 1 Bristol-Myers Squibb · Anaheim, California · NCT07283263

• Ozanimod versus azathioprine for steroid-dependent ulcerative colitis

  This study will see if ozanimod works better than azathioprine for adults in Japan who are dependent on high-dose steroids for ulcerative colitis.

  Recruiting at 13 sites Bristol-Myers Squibb · Chiba, Chiba and 17 other locations · NCT07271069

• How different BMS-986435 tablets are absorbed and whether food changes absorption

  This will test whether different tablet versions of BMS-986435 are absorbed differently in healthy adults and whether taking the tablet with food changes absorption.

  Recruiting Phase 1 Bristol-Myers Squibb · Miami, Florida · NCT07226817

• BMS-986523 alone and with other cancer medicines for advanced KRAS-altered solid tumors

  This treatment tests whether BMS-986523, alone or combined with chemotherapy or immunotherapy, helps people with advanced KRAS-altered lung, colorectal, or pancreatic cancers.

  Recruiting at 6 sites Phase 1/2 Bristol-Myers Squibb · Baltimore, Maryland and 7 other locations · NCT07223047

• KarXT's effects on bladder and urinary function

  This trial will test whether KarXT affects bladder emptying and other urinary safety measures in adults with schizophrenia who can stop other antipsychotics.

  Recruiting at 15 sites Phase 4 Bristol-Myers Squibb · Little Rock, Arkansas and 15 other locations · NCT07221877

• Pumitamig plus chemotherapy versus bevacizumab plus chemotherapy for untreated metastatic colorectal cancer

  This trial tests whether adding the new drug pumitamig to standard chemotherapy works better than bevacizumab plus chemotherapy for people with previously untreated, unresectable, or metastatic colorectal cancer who do not have MSI‑H/dMMR or BRAF V600E mutations.

  Recruiting at 209 sites Phase 2/3 Bristol-Myers Squibb · Tucson, Arizona and 285 other locations · NCT07221357

• Pumitamig plus chemotherapy versus nivolumab plus chemotherapy for untreated advanced gastric, gastroesophageal junction, or distal esophageal adenocarcinoma

  This trial will try Pumitamig with chemotherapy versus nivolumab with chemotherapy in people with previously untreated advanced or metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma.

  Recruiting at 106 sites Phase 2/3 Bristol-Myers Squibb · Phoenix, Arizona and 160 other locations · NCT07221149

• Luspatercept for adults with transfusion-dependent beta-thalassemia in the Middle East

  This project tests whether luspatercept can reduce blood transfusion needs in adults with transfusion-dependent beta-thalassemia in the Middle East.

  Recruiting at 4 sites Bristol-Myers Squibb · Al Jahra and 12 other locations · NCT07215975

• First human testing of BMS-986506 in advanced clear cell kidney cancer

  This will test whether the experimental drug BMS-986506 is safe and tolerable when taken alone by people with advanced or metastatic clear cell kidney cancer who have already received prior treatments.

  Recruiting at 9 sites Phase 1 Bristol-Myers Squibb · Boston, Massachusetts and 10 other locations · NCT07195682

• Treatment outcomes for people with active SLE not helped by steroids and multiple immunosuppressants

  It will see how well current treatments work and how safe they are for people with active SLE who haven't had enough benefit from glucocorticoids and at least two immunosuppressant drugs.

  Recruiting at 53 sites Bristol-Myers Squibb · La Jolla, California and 69 other locations · NCT07175285

• BMS-986454 for adults with rheumatoid arthritis who had an incomplete response to methotrexate.

  This trial will test whether BMS-986454 is safe and how the drug behaves in adults with rheumatoid arthritis who did not fully respond to methotrexate.

  Recruiting at 5 sites Phase 1 Bristol-Myers Squibb · Hyderabad, Andhra Pradesh and 8 other locations · NCT07171983

• First-in-human testing of BMS-986517 in advanced solid tumors

  This trial will test the experimental drug BMS-986517 in adults with advanced, unresectable or metastatic solid tumors such as non-small cell lung cancer, head and neck cancer, and certain breast cancers.

  Recruiting at 14 sites Phase 1/2 Bristol-Myers Squibb · Irvine, California and 19 other locations · NCT07160725

• KarXT added to lithium, valproate, or lamotrigine for treating mania in Bipolar I

  This will test whether adding KarXT to a stable mood stabilizer (lithium, valproate, or lamotrigine) helps adults hospitalized for an acute manic episode of bipolar I disorder reduce their manic symptoms.

  Recruiting at 75 sites Phase 3 Bristol-Myers Squibb · Bentonville, Arkansas and 108 other locations · NCT07140913

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Izalontamab Brengitecan versus Platinum Chemotherapy for Advanced Urothelial Cancer

  This trial tests whether izalontamab brengitecan works better than standard platinum-based chemotherapy for people with metastatic urothelial (bladder) cancer that progressed after prior immunotherapy.

  Recruiting at 122 sites Phase 2/3 Bristol-Myers Squibb · Gilbert, Arizona and 162 other locations · NCT07106762

• Treatment satisfaction and use of KarXT (xanomeline + trospium) for adults with schizophrenia

  This registry will collect information from adults with schizophrenia in the U.S. who start KarXT (xanomeline plus trospium) to see how satisfied they are with the treatment and how it's used.

  Recruiting at 14 sites Bristol-Myers Squibb · Orange, California and 19 other locations · NCT07101094

• Izalontamab brengitecan versus platinum-pemetrexed for EGFR‑mutated non‑small cell lung cancer after EGFR TKI failure

  This trial tests whether izalontamab brengitecan works better than platinum‑pemetrexed chemotherapy for people with EGFR‑mutated non‑small cell lung cancer that has progressed after third‑generation EGFR TKI treatment.

  Recruiting at 45 sites Phase 2/3 Bristol-Myers Squibb · Irvine, California and 186 other locations · NCT07100080

• Safety and drug-level testing of BMS-986504 for advanced solid tumors with MTAP deletion

  This trial tests whether BMS-986504 is safe, tolerable, and reaches acceptable drug levels in adults with advanced solid tumors that have an MTAP gene deletion.

  Recruiting at 12 sites Phase 1 Bristol-Myers Squibb · Beijing, Beijing Municipality and 11 other locations · NCT07077434

• BMS-986504 plus pembrolizumab and chemotherapy for first-line metastatic NSCLC with MTAP deletion

  This study will test whether adding BMS-986504 to pembrolizumab and platinum chemotherapy helps people with first-line metastatic NSCLC who have a homozygous MTAP deletion.

  Recruiting at 191 sites Phase 2/3 Bristol-Myers Squibb · Anchorage, Alaska and 320 other locations · NCT07063745

• Compare new KarX and KarT pill versions with KarXT and KarX-EC and check food effects in healthy adults

  This test will compare new KarX and KarT medication prototypes against the existing KarXT and KarX-EC formulations and see how eating affects selected prototypes when taken multiple times by healthy adults.

  Recruiting Phase 1 Bristol-Myers Squibb · Nottingham, Nottinghamshire · NCT07063342

• Single KarXT intramuscular injection to test dosing and safety in people with schizophrenia

  This will test whether a single intramuscular injection of KarXT is safe and what drug levels it produces in adults with schizophrenia who can stop other antipsychotic medications.

  Recruiting at 8 sites Phase 1 Bristol-Myers Squibb · Los Alamitos, California and 7 other locations · NCT07061288

• Deucravacitinib safety during pregnancy.

  This project will see if taking deucravacitinib during pregnancy affects pregnancy and baby outcomes for people with psoriasis.

  Recruiting Bristol-Myers Squibb · La Jolla, California · NCT07017699

• KarXT + KarX-EC for treating agitation in Alzheimer's disease

  This will test whether combining KarXT and KarX-EC reduces agitation in adults with Alzheimer's disease.

  Recruiting at 99 sites Phase 3 Bristol-Myers Squibb · Chandler, Arizona and 142 other locations · NCT07011745

• KarXT plus KarX-EC for treating agitation in Alzheimer's disease

  This trial will test whether taking KarXT together with KarX-EC can reduce agitation in adults with Alzheimer's disease.

  Recruiting at 120 sites Phase 3 Bristol-Myers Squibb · Scottsdale, Arizona and 161 other locations · NCT07011732

• BMS-986500 alone or with other therapies for advanced solid tumors

  This trial will test whether BMS-986500 by itself or combined with palbociclib and fulvestrant can help adults with advanced solid tumors, including breast and ovarian cancers, especially after CDK4/6 inhibitor treatment.

  Recruiting at 18 sites Phase 1 Bristol-Myers Squibb · Birmingham, Alabama and 20 other locations · NCT06997029

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• KarXT plus KarX-EC for thinking and memory problems in mild-to-moderate Alzheimer's disease

  This trial will test whether the combination of KarXT and KarX-EC can help thinking and memory in people with mild-to-moderate Alzheimer's disease.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Long Beach, California and 118 other locations · NCT06976216

• KarXT plus KarX-EC for cognitive impairment in Alzheimer's disease (MINDSET 2)

  This trial will try to see if combining KarXT and KarX-EC can improve thinking, memory, and daily functioning in people with mild to moderate Alzheimer's disease.

  Recruiting at 109 sites Phase 3 Bristol-Myers Squibb · Fullerton, California and 127 other locations · NCT06976203

• KarXT for treating manic episodes in bipolar I disorder (BALSAM-2)

  This trial tests whether KarXT helps adults hospitalized for an acute manic episode of bipolar I disorder (including mixed features) compared with placebo during a 3-week inpatient treatment.

  Recruiting at 57 sites Phase 3 Bristol-Myers Squibb · Little Rock, Arkansas and 85 other locations · NCT06951711

• KarXT for manic episodes in Bipolar I disorder

  This trial will test whether KarXT can reduce manic symptoms in adults hospitalized for an acute manic episode of Bipolar I disorder during a three-week inpatient treatment period.

  Recruiting at 59 sites Phase 3 Bristol-Myers Squibb · Bentonville, Arkansas and 73 other locations · NCT06951698

• KarXT plus KarX-EC for psychosis in Alzheimer's disease

  This trial tests whether taking KarXT together with KarX-EC can reduce hallucinations and delusions in people aged 55–90 with psychosis related to Alzheimer's disease.

  Recruiting at 3 sites Phase 3 Bristol-Myers Squibb · Gilbert, Arizona and 21 other locations · NCT06947941

• Long-term KarXT plus KarX-EC treatment for agitation in Alzheimer’s disease

  This will test whether taking KarXT together with KarX-EC reduces agitation and is safe long-term in people with Alzheimer’s disease who completed the earlier parent studies.

  Recruiting at 58 sites Phase 3 Bristol-Myers Squibb · Chandler, Arizona and 251 other locations · NCT06937229

• Long-term KarXT safety for manic episodes in bipolar I (BALSAM-3)

  This open-label phase 3 study will test whether long-term KarXT is safe and tolerable for adults with bipolar I disorder experiencing mania or mixed mania.

  Recruiting at 127 sites Phase 3 Bristol-Myers Squibb · Glendale, Arizona and 183 other locations · NCT06929273

• Izalontamab brengitecan versus chemotherapy for first-line metastatic triple-negative or ER-low, HER2-negative breast cancer in patients not eligible for anti-PD(L)1 drugs

  This trial tests whether iza-bren (izalontamab brengitecan), a bi‑specific antibody‑drug conjugate, works better than standard chemotherapy as first-line treatment for people with metastatic triple‑negative or ER‑low, HER2‑negative breast cancer who cannot receive anti‑PD(L)1 drugs.

  Recruiting at 168 sites Phase 2/3 Bristol-Myers Squibb · Hot Springs, Arkansas and 294 other locations · NCT06926868

• KarXT for acute psychosis in Japanese adults with schizophrenia

  This trial will test whether KarXT can reduce acute psychotic symptoms in Japanese adults with schizophrenia compared with placebo.

  Recruiting at 46 sites Phase 3 Bristol-Myers Squibb · Kōnan, Aichi-ken and 55 other locations · NCT06882785

• Continued deucravacitinib treatment for people with systemic or cutaneous lupus who completed earlier trials

  This open-label extension lets people with systemic lupus or discoid/subacute cutaneous lupus who finished specific earlier trials continue taking deucravacitinib to see if ongoing treatment remains safe and tolerable.

  Recruiting at 2 sites Phase 4 Bristol-Myers Squibb · Farmington, Connecticut and 3 other locations · NCT06875960

• Evaluating Deucravacitinib for Juvenile Psoriatic Arthritis in Children

  This study is testing if a new medication called Deucravacitinib can help children with juvenile psoriatic arthritis who haven't had success with other treatments.

  Recruiting at 29 sites Phase 3 Bristol-Myers Squibb · Lancaster, California and 47 other locations · NCT06869551

• Evaluating BMS-986504 for advanced lung cancer with specific genetic deletion

  This study is testing a new drug called BMS-986504 to see if it can help people with advanced lung cancer who have a specific genetic change and have not responded to previous treatments.

  Recruiting at 65 sites Phase 2 Bristol-Myers Squibb · Anchorage, Alaska and 66 other locations · NCT06855771

• Testing BMS-986488 for advanced malignant tumors

  This study is testing a new treatment called BMS-986488 to see if it can help people with advanced cancers feel better and fight their disease, either on its own or with other therapies.

  Recruiting at 4 sites Phase 1 Bristol-Myers Squibb · Hackensack, New Jersey and 7 other locations · NCT06764771

• Evaluating the effectiveness of deucravacitinib for plaque psoriasis in adults in France

  This study is testing how well deucravacitinib works for adults with moderate-to-severe plaque psoriasis in real life.

  Recruiting at 39 sites Bristol-Myers Squibb · Amiens and 47 other locations · NCT06701513

• Monitoring long-term safety of idecabtagene vicleucel in newly diagnosed multiple myeloma patients in Korea

  This study is testing the long-term safety of a treatment called idecabtagene vicleucel in adults with newly diagnosed multiple myeloma who didn't respond well after their stem cell transplant.

  Recruiting at 5 sites Bristol-Myers Squibb · Hwasun, Jeonranamdo and 4 other locations · NCT06698887

• Testing BMS-986482 for advanced solid tumors

  This study is testing a new treatment called BMS-986482, alone and with other therapies, to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 20 sites Phase 1/2 Bristol-Myers Squibb · Irvine, California and 20 other locations · NCT06697197

• Evaluating a new drug for advanced solid tumors with a specific genetic deletion

  This study is testing a new drug for people with advanced solid tumors that have a specific genetic change to see how the drug works in their bodies.

  Recruiting at 3 sites Phase 1 Bristol-Myers Squibb · Budapest and 2 other locations · NCT06672523

• Comparing two treatments for extensive-stage small cell lung cancer

  This study is testing a new treatment combination for extensive-stage small cell lung cancer to see if it works better and is safer than the standard treatment.

  Recruiting at 18 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 182 other locations · NCT06646276

• Evaluating a new drug combination for advanced lung cancer

  This study is testing a new combination of drugs for adults with advanced lung cancer to see if it is safe and effective when used with existing treatments.

  Recruiting at 47 sites Phase 1/2 Bristol-Myers Squibb · Birmingham, Alabama and 64 other locations · NCT06618287

• Comparing two treatments for advanced non-small cell lung cancer

  This study is testing whether a combination of Nivolumab and Relatlimab with chemotherapy works better than Pembrolizumab with chemotherapy for people with advanced lung cancer.

  Recruiting at 239 sites Phase 3 Bristol-Myers Squibb · Mobile, Alabama and 329 other locations · NCT06561386

• Assessing health changes in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten

  This study is testing how well the medication mavacamten helps adults with obstructive hypertrophic cardiomyopathy feel and do better in their everyday lives.

  Recruiting Bristol-Myers Squibb · Boston, Massachusetts · NCT06551129

• Evaluating BMS-986470 in healthy individuals and those with sickle cell disease

  This study is testing a new drug called BMS-986470 to see how safe it is and how well it works in both healthy people and those with sickle cell disease.

  Recruiting at 14 sites Phase 1/2 Bristol-Myers Squibb · Birmingham, Alabama and 31 other locations · NCT06481306

• Evaluating a new treatment for advanced malignant tumors

  This study is testing a new drug called BMS-986463 to see if it is safe and effective for people with advanced cancers like ovarian and lung cancer.

  Recruiting at 7 sites Phase 1 Bristol-Myers Squibb · Los Angeles, California and 16 other locations · NCT06476808

• Evaluating Ozanimod versus Fingolimod for Children with Relapsing Remitting Multiple Sclerosis

  This study is testing whether ozanimod works better than fingolimod for children and teens with relapsing remitting multiple sclerosis.

  Recruiting at 20 sites Phase 3 Bristol-Myers Squibb · Loma Linda, California and 32 other locations · NCT06408259

• Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan

  This study is testing whether a new medication called deucravacitinib works better than apremilast for adults with plaque psoriasis in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT06382987

• Testing tumor samples from patients with second cancers after gene therapy

  This study is testing tumor samples from patients who have had gene therapy to see if there's a link between the treatment and the development of a second cancer.

  Recruiting at 5 sites Bristol-Myers Squibb · Portland, Oregon and 7 other locations · NCT06357754

• Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea

  This study is testing if a new medication called Sotyktu is safe and effective for adults in Korea with moderate-to-severe plaque psoriasis who need treatment.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06258668

• Evaluating nivolumab with chemotherapy for early-stage lung cancer in Germany

  This study is testing whether combining nivolumab with chemotherapy can improve treatment outcomes for people in Germany with early-stage lung cancer that can be surgically removed.

  Recruiting Bristol-Myers Squibb · Kempten (Allgäu), Bavaria · NCT06169956

• Assessing the safety of mavacamten in Korean patients with obstructive hypertrophic cardiomyopathy

  This study is testing how safe the medication mavacamten is for adults in Korea who have symptoms of obstructive hypertrophic cardiomyopathy.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06146660

• Assessing BMS-986458 for treating relapsed non-Hodgkin lymphoma

  This study is testing a new drug called BMS-986458 to see if it can help people with relapsed non-Hodgkin lymphoma when used alone or with standard treatments like Rituximab.

  Recruiting at 35 sites Phase 1/2 Bristol-Myers Squibb · Phoenix, Arizona and 75 other locations · NCT06090539

• Assessing the safety of ozanimod for ulcerative colitis in Korea

  This study is testing how safe the medication ozanimod is for adults with moderate to severe ulcerative colitis in Korea.

  Recruiting Bristol-Myers Squibb · Seoul · NCT06073873

• Assessing the safety of luspatercept in Korean patients with myelodysplastic syndrome or beta thalassemia

  This study is testing how safe the drug luspatercept is for adult Korean patients with myelodysplastic syndrome or beta thalassemia while they are being treated.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06073860

• Assessing the safety of fedratinib in Korean patients with myelofibrosis

  This study is testing the safety of a drug called fedratinib in adults with myelofibrosis who haven't responded well to or can't tolerate another treatment called ruxolitinib.

  Recruiting at 2 sites Bristol-Myers Squibb · Seoul and 2 other locations · NCT06073847

• Assessing the safety of oral azacitidine for Korean patients with acute myeloid leukemia

  This study is testing how safe oral azacitidine is for Korean adults with acute myeloid leukemia who have gone into remission after chemotherapy.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06073769

• Assessing BMS-986460 for advanced prostate cancer

  This study is testing a new treatment called BMS-986460 to see if it can help men with advanced prostate cancer who haven't responded to other therapies.

  Recruiting at 10 sites Phase 1 Bristol-Myers Squibb · Palo Alto, California and 14 other locations · NCT06067841

• Ozanimod in pregnancy for ulcerative colitis: how it affects moms and babies

  This study looks to see if taking ozanimod during pregnancy changes outcomes for mothers, babies, or infants in people with ulcerative colitis.

  Recruiting Bristol-Myers Squibb · Wilmington, North Carolina · NCT05953402

• Monitoring the effects of mavacamten during pregnancy and breastfeeding

  This study is testing how safe the heart medication mavacamten is for mothers and their babies during pregnancy and breastfeeding.

  Recruiting Bristol-Myers Squibb · Wilmington, North Carolina · NCT05939700

• Comparing the effectiveness of two medications for plaque psoriasis

  This study is testing whether deucravacitinib or apremilast works better for adults with plaque psoriasis who are starting treatment.

  Recruiting Bristol-Myers Squibb · Waltham, Massachusetts · NCT05744466

• Registry to assess patient characteristics and outcomes in obstructive hypertrophic cardiomyopathy

  This study is trying to learn more about how people with obstructive hypertrophic cardiomyopathy are treated and what their experiences are, especially for those using the medication mavacamten.

  Recruiting at 76 sites Bristol-Myers Squibb · Anchorage, Alaska and 100 other locations · NCT05489705

• Evaluating a new treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of treatments for people with relapsed or refractory multiple myeloma to see if it can help them feel better after other treatments have failed.

  Recruiting at 15 sites Phase 1/2 Bristol-Myers Squibb · Birmingham, Alabama and 16 other locations · NCT05372354

• Testing MRTX1719 for solid tumors with MTAP deletion

  This study is testing a new drug called MRTX1719 to see if it can help people with advanced solid tumors that have a specific gene deletion.

  Recruiting at 22 sites Phase 1 Bristol-Myers Squibb · Phoenix, Arizona and 24 other locations · NCT05245500

• Examining the safety of ozanimod in pregnant women with multiple sclerosis

  This study is trying to see how safe the medication ozanimod is for pregnant women with multiple sclerosis and their babies.

  Recruiting at 3 sites Bristol-Myers Squibb · Bethesda, Maryland and 2 other locations · NCT05170126

• Investigating Ozanimod for Children with Moderate to Severe Ulcerative Colitis

  This study is testing a new oral medication called ozanimod to see if it can help children with moderate to severe ulcerative colitis feel better and stay well after other treatments haven't worked.

  Recruiting at 41 sites Phase 2/3 Bristol-Myers Squibb · Phoenix, Arizona and 90 other locations · NCT05076175

• Testing BMS-986340 alone and with other treatments for advanced solid tumors

  This study is testing a new treatment called BMS-986340, both on its own and with other drugs, to see how safe it is for people with advanced solid tumors.

  Recruiting at 39 sites Phase 1/2 Bristol-Myers Squibb · Clovis, California and 46 other locations · NCT04895709

• Evaluating a new immunosuppressive regimen for adolescent kidney transplant recipients

  This study is testing whether switching adolescent kidney transplant recipients from their current medication to a new one called belatacept can improve their kidney function and overall health.

  Recruiting at 16 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 37 other locations · NCT04877288

• Evaluating Deucravacitinib for Pediatric Plaque Psoriasis

  This study is testing a new medication called Deucravacitinib to see if it helps children and teens with moderate to severe plaque psoriasis feel better and is safe for them to use.

  Recruiting at 45 sites Phase 3 Bristol-Myers Squibb · Ciudad Autonoma de Buenos Aires, Buenos Aires and 64 other locations · NCT04772079

• Long-term safety evaluation of nivolumab and other cancer therapies

  This study is testing the long-term safety of nivolumab alone and with other cancer treatments for patients who have responded well to previous therapies.

  Recruiting at 109 sites Phase 2 Bristol-Myers Squibb · Huntsville, Alabama and 409 other locations · NCT03899155

Quick answers

How many clinical trials run by Bristol-Myers Squibb are recruiting right now?

102, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 53 countries. The most sites are in United States (72 trials), Spain (45 trials), Japan (43 trials), Italy (39 trials), France (38 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 25, Phase 1: 20, Phase 1/2: 12, Phase 2/3: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →